Dental equipment manufacturer Sonendo, Inc., is considering a strategic move to acquire assets from its industry peer, Biolase (OTC:BIOL), Inc., which is facing potential bankruptcy. In a recent SEC filing, Sonendo disclosed that its subsidiary has entered into a preliminary agreement with Biolase as of August 30, 2024.
The non-binding letter of intent suggests Sonendo's intention to act as a "stalking horse bidder" in a potential Chapter 11 bankruptcy case for Biolase, which may be filed in the United States Bankruptcy Court for the District of Delaware. A stalking horse bid is an initial bid on a bankrupt company's assets, setting the bar for potential additional offers.
To navigate this process, Sonendo has enlisted the expertise of financial advisory firms Craig-Hallum Capital Group LLC and Stifel. This move could expand Sonendo's footprint in the dental equipment market, although the details of the assets and terms of the potential sale remain under evaluation.
Sonendo, which is traded on the OTC Markets under the ticker SONX, is a Delaware-incorporated company primarily known for its innovative dental technologies. The company's interest in Biolase assets marks a significant development in the dental equipment sector, which could reshape competitive dynamics.
Investors are keeping a close watch on the unfolding events, as the acquisition could have implications for Sonendo's market positioning and financial health. The company's management has yet to provide further details on the potential deal, and it is important to note that the current discussions are based on a non-binding agreement, meaning plans could change.
The information regarding these recent developments was based on a press release statement filed with the SEC. Sonendo's consideration to acquire Biolase's assets reflects ongoing consolidation trends within the dental equipment industry, although the outcome of this interest remains to be seen.
In other recent news, Sonendo Inc. reported its Q2 2024 financial results, posting a total revenue of $8.3 million, despite a year-over-year decrease. The company saw a 7% increase in console sales and adjusted its full-year revenue guidance to range between $31 million and $32 million. Sonendo also reported a GAAP gross margin of 37.5% for the quarter, with projections of adjusted gross margins reaching 40% to 41% in the second half of 2024.
Amid these developments, Sonendo announced the departure of its Chief Talent Officer, Roy T. Chen, who is leaving the company to pursue another opportunity. Following his departure, the Human Resources organization will come under the purview of John Bostjancic, Sonendo’s Chief Financial Officer.
In a significant move, Sonendo engaged BDO USA, P.C. as its new auditor, replacing Ernst & Young LLP (EY). This decision followed EY's concerns about Sonendo's recurring losses and raised substantial doubt about the company's ability to continue as a going concern.
Looking forward, Sonendo is actively exploring financing options to strengthen its balance sheet. The company also anticipates a reduction in adjusted EBITDA loss in the second half of 2024 and aims to return to double-digit revenue growth in 2025.
InvestingPro Insights
As Sonendo, Inc. explores the strategic acquisition of assets from Biolase, Inc., real-time data and InvestingPro Tips provide a clearer picture of Sonendo's financial position. According to InvestingPro data, Sonendo's market capitalization stands at a modest 1.76M USD, with a Price / Book ratio for the last twelve months as of Q2 2024 at a low 0.11, indicating that the stock may be undervalued relative to its book value. This could be a factor in Sonendo's ability to pursue acquisitions.
InvestingPro Tips highlight that Sonendo holds more cash than debt on its balance sheet, which is a positive indicator of financial stability and could give the company an edge in the acquisition process. Additionally, with an RSI suggesting the stock is in oversold territory, investors might be witnessing a potential turnaround point for the company's shares.
Moreover, the company has been aggressively buying back shares, reflecting management's confidence in Sonendo's future prospects. This could be of interest to investors considering the company's strategic moves, such as the potential acquisition of Biolase's assets.
For those seeking more in-depth analysis, there are over 18 additional InvestingPro Tips available at https://www.investing.com/pro/SONX, providing a comprehensive view of Sonendo's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.